You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTizanidine
Accession NumberDB00697  (APRD00128)
TypeSmall Molecule
GroupsApproved
DescriptionTizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
Structure
Thumb
Synonyms
5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole
Tizanidin
Tizanidina
Tizanidine
Tizanidinum
External Identifiers
  • AN 021
  • DS 103-282
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mylan-tizanidinetablet4 mgoralMylan Pharmaceuticals Ulc2006-02-16Not applicableCanada
Pal-tizanidinetablet4 mgoralPaladin Labs Inc1999-10-29Not applicableCanada
Tizanidinetablet4 mgoralAa Pharma Inc2004-11-17Not applicableCanada
Tizanidinetablet2 mgoralAa Pharma IncNot applicableNot applicableCanada
Tizanidine Hydrochloridecapsule, gelatin coated2 mg/1oralActavis Pharma, Inc.2012-02-06Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated6 mg/1oralbryant ranch prepack2012-02-06Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated4 mg/1oralActavis Pharma, Inc.2012-02-06Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated6 mg/1oralActavis Pharma, Inc.2012-02-06Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated2 mg/1oralClinical Solutions Wholesale2012-02-06Not applicableUs
Zanaflexcapsule6 mg/1oralSTAT Rx USA LLC2002-08-29Not applicableUs
Zanaflexcapsule4 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-28Not applicableUs
Zanaflexcapsule2 mg/1oralAcorda Therapeutics, Inc.2005-04-04Not applicableUs
Zanaflexcapsule4 mg/1oralSTAT Rx USA LLC2002-08-29Not applicableUs
Zanaflexcapsule6 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-28Not applicableUs
Zanaflexcapsule4 mg/1oralAcorda Therapeutics, Inc.2005-04-04Not applicableUs
Zanaflexcapsule, gelatin coated4 mg/1oralRebel Distributors Corp2002-08-29Not applicableUs
Zanaflextablet4 mg/1oralPd Rx Pharmaceuticals, Inc.1997-01-01Not applicableUs
Zanaflexcapsule6 mg/1oralAcorda Therapeutics, Inc.2005-04-04Not applicableUs
Zanaflexcapsule2 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-28Not applicableUs
Zanaflextablet4 mg/1oralAcorda Therapeutics, Inc.1997-01-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Comfort Pac With TizanidinekitPd Rx Pharmaceuticals, Inc.2013-07-09Not applicableUs
Tizanidinetablet4 mg/1oralCore Pharma, Llc2007-02-06Not applicableUs
Tizanidinetablet4 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-03Not applicableUs
Tizanidinetablet4 mg/1oralAidarex Pharmaceuticals LLC2002-07-03Not applicableUs
Tizanidinetablet4 mg/1oralREMEDYREPACK INC.2014-11-21Not applicableUs
Tizanidinetablet4 mg/1oralCardinal Health2002-07-032016-03-22Us
Tizanidinetablet4 mg/1oralProficient Rx LP2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralPreferred Pharmaceuticals, Inc.2014-03-26Not applicableUs
Tizanidinetablet2 mg/1oralSTAT Rx USA LLC2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Tizanidinetablet4 mg/1oralBlenheim Pharmacal, Inc.2014-01-22Not applicableUs
Tizanidinetablet4 mg/1oralUnit Dose Services2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralPd Rx Pharmaceuticals, Inc.2002-11-26Not applicableUs
Tizanidinetablet2 mg/1oralREMEDYREPACK INC.2015-12-16Not applicableUs
Tizanidinetablet2 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-04-01Not applicableUs
Tizanidinetablet2 mg/1oralAphena Pharma Solutions Tennessee, Llc2003-05-06Not applicableUs
Tizanidinetablet2 mg/1oralPhysicians Total Care, Inc.2004-03-03Not applicableUs
Tizanidinetablet2 mg/1oralApotex Corp.2004-01-16Not applicableUs
Tizanidinetablet2 mg/1oralbryant ranch prepack2002-07-03Not applicableUs
Tizanidinetablet4 mg/1oralPreferred Pharmaceuticals Inc.2016-03-16Not applicableUs
Tizanidinetablet4 mg/1oralCardinal Health2011-01-28Not applicableUs
Tizanidinetablet4 mg/1oralDispensing Solutions, Inc.2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-03Not applicableUs
Tizanidinetablet4 mg/1oralH.J. Harkins Company, Inc.2002-07-03Not applicableUs
Tizanidinetablet4 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Tizanidinetablet4 mg/1oralProficient Rx LP2004-01-16Not applicableUs
Tizanidinetablet4 mg/1oralPreferred Pharmaceuticals, Inc.2014-03-05Not applicableUs
Tizanidinetablet4 mg/1oralSTAT Rx USA LLC2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralBlenheim Pharmacal, Inc.2014-01-13Not applicableUs
Tizanidinetablet4 mg/1oralMylan Institutional Inc.2003-06-15Not applicableUs
Tizanidinetablet2 mg/1oralSun Pharmaceutical Industries, Inc.2003-12-11Not applicableUs
Tizanidinetablet4 mg/1oralProficient Rx LP2003-12-11Not applicableUs
Tizanidinetablet4 mg/1oralUnichem Pharmaceuticals (USA), Inc.2013-04-01Not applicableUs
Tizanidinetablet4 mg/1oralMedsource Pharmaceuticals2008-12-08Not applicableUs
Tizanidinetablet2 mg/1oralDr. Reddy's Laboratories Limited2002-07-03Not applicableUs
Tizanidinetablet4 mg/1oralApotex Corp.2004-01-16Not applicableUs
Tizanidinetablet2 mg/1oralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Tizanidinetablet2 mg/1oralAv Kare, Inc.2015-07-23Not applicableUs
Tizanidinetablet2 mg/1oralCardinal Health2013-03-21Not applicableUs
Tizanidinetablet2 mg/1oralSt. Mary's Medical Park Pharmacy2015-08-18Not applicableUs
Tizanidinetablet4 mg/1oralAmerican Health Packaging2013-09-25Not applicableUs
Tizanidinetablet2 mg/1oralMylan Pharmaceuticals Inc.2003-05-06Not applicableUs
Tizanidinetablet4 mg/1oralPd Rx Pharmaceuticals, Inc.2012-07-24Not applicableUs
Tizanidinetablet2 mg/1oralH.J. Harkins Company, Inc.2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralGolden State Medical Supply, Inc.2004-01-16Not applicableUs
Tizanidinetablet4 mg/1oralProficient Rx LP2013-04-01Not applicableUs
Tizanidinetablet4 mg/1oralMc Kesson Contract Packaging2012-02-23Not applicableUs
Tizanidinetablet2 mg/1oralPreferred Pharmaceuticals, Inc2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralBlenheim Pharmacal, Inc.2014-04-08Not applicableUs
Tizanidinetablet4 mg/1oralREMEDYREPACK INC.2013-02-19Not applicableUs
Tizanidinetablet4 mg/1oralSun Pharmaceutical Industries, Inc.2003-12-11Not applicableUs
Tizanidinetablet2 mg/1oralDIRECT RX2014-01-01Not applicableUs
Tizanidinetablet2 mg/1oralCore Pharma, Llc2007-02-06Not applicableUs
Tizanidinetablet2 mg/1oralAidarex Pharmaceuticals LLC2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralMedsource Pharmaceuticals2009-01-05Not applicableUs
Tizanidinetablet4 mg/1oralDr. Reddy's Laboratories Limited2002-07-03Not applicableUs
Tizanidinetablet4.576 mg/1oralMajor Pharmaceuticals2014-10-01Not applicableUs
Tizanidinetablet4 mg/1oralAv Kare, Inc.2015-07-23Not applicableUs
Tizanidinetablet2 mg/1oralUnit Dose Services2002-07-03Not applicableUs
Tizanidinetablet2 mg/1oralREMEDYREPACK INC.2015-09-03Not applicableUs
Tizanidinetablet2 mg/1oralAmerican Health Packaging2014-06-02Not applicableUs
Tizanidinetablet4 mg/1oralMylan Pharmaceuticals Inc.2003-05-06Not applicableUs
Tizanidinetablet4 mg/1oralAphena Pharma Solutions Tennessee, Llc2003-05-06Not applicableUs
Tizanidinetablet4 mg/1oralPhysicians Total Care, Inc.2004-01-19Not applicableUs
Tizanidinetablet4 mg/1oralGolden State Medical Supply, Inc.2004-01-16Not applicableUs
Tizanidinetablet4 mg/1oralbryant ranch prepack2002-07-03Not applicableUs
Tizanidinetablet4 mg/1oralDIRECT RX2014-01-01Not applicableUs
Tizanidinetablet4 mg/1oralPreferred Pharmaceuticals, Inc2002-07-03Not applicableUs
Tizanidinetablet4 mg/1oralBlenheim Pharmacal, Inc.2014-12-18Not applicableUs
Tizanidinetablet2 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs
Tizanidinetablet2 mg/1oralClinical Solutions Wholesale2002-07-03Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated4 mg/1oralApotex Corp.2012-02-06Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralClinical Solutions Wholesale2002-06-27Not applicableUs
Tizanidine Hydrochloridetablet2 mg/1oralEon Labs, Inc.2002-11-26Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralSTAT Rx USA LLC2002-06-27Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated2 mg/1oralAv Kare, Inc.2014-06-20Not applicableUs
Tizanidine Hydrochloridetablet2 mg/1oralKeltman Pharmaceuticals Inc.2005-06-01Not applicableUs
Tizanidine Hydrochloridecapsule2 mg/1oralMylan Pharmaceuticals Inc.2013-03-01Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated6 mg/1oralApotex Corp.2012-02-06Not applicableUs
Tizanidine Hydrochloridetablet2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-02-06Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-11-23Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralEon Labs, Inc.2002-06-27Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated4 mg/1oralAv Kare, Inc.2014-06-20Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralTIZANIDINE HYDROCHLORIDE2014-01-01Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralKeltman Pharmaceuticals Inc.2005-06-01Not applicableUs
Tizanidine Hydrochloridecapsule4 mg/1oralMylan Pharmaceuticals Inc.2013-03-01Not applicableUs
Tizanidine Hydrochloridetablet2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-04-20Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralMajor Pharmaceuticals2010-07-16Not applicableUs
Tizanidine Hydrochloridetablet2 mg/1oralRebel Distributors2007-02-06Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated6 mg/1oralAv Kare, Inc.2014-06-20Not applicableUs
Tizanidine Hydrochloridecapsule, gelatin coated2 mg/1oralApotex Corp.2012-02-06Not applicableUs
Tizanidine Hydrochloridecapsule6 mg/1oralMylan Pharmaceuticals Inc.2013-03-01Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralPd Rx Pharmaceuticals, Inc.2002-06-27Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralRebel Distributors2007-02-06Not applicableUs
Tizanidine Hydrochloridetablet4 mg/1oralAmerican Health Packaging2013-07-082015-12-29Us
Tizanidine Hydrochloridetablet2 mg/1oralSTAT Rx USA LLC2002-11-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CimbrarEuroetika
MusantActavis
MyoresMeprofarm
NavizanCaber
RelaxkovBlaskov
SirdalidNovartis
SirdaludNovartis
Sirdalud MRNovartis
SizolanDr. Reddy's
SpaslaxPanion & BF
TelzanineNisshin Seiyaku
TernelinNovartis
TizadinACL
TizaflexActavis
TizaludOpsonin
TizanSun
ZanpeakTatsumi Kagaku
ZitanidNovell
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tizanidine Hydrochloride
Thumb
  • InChI Key: ZWUKMNZJRDGCTQ-UHFFFAOYSA-N
  • Monoisotopic Mass: 288.995571417
  • Average Mass: 290.172
DBSALT000550
Categories
UNII6AI06C00GW
CAS number51322-75-9
WeightAverage: 253.711
Monoisotopic: 253.018893678
Chemical FormulaC9H8ClN5S
InChI KeyInChIKey=XFYDIVBRZNQMJC-UHFFFAOYSA-N
InChI
InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
IUPAC Name
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
SMILES
ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazoles. These are heterocyclic aromatic compounds containing a benzene ring fused to a thiadiazole ring. Thiadiazole is a five-membered aromatic heterocycle made up of one sulfur atom and two nitrogen atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiadiazoles
Sub ClassNot Available
Direct ParentBenzothiadiazoles
Alternative Parents
Substituents
  • 2,1,3-benzothiadiazole
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Thiadiazole
  • 2-imidazoline
  • Azole
  • Guanidine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of increased muscle tone associated with spasticity
PharmacodynamicsTizanidine is a short-acting drug for the management of spasticity. Tizanidine is an agonist at a2-adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
Mechanism of actionTizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 2.4 L/kg
Protein binding30%
Metabolism
SubstrateEnzymesProduct
Tizanidine
5-chloro-4-(guanidino)-2,1,3-benzothiadiazoleDetails
Tizanidine
5-chloro-4-(2-imidazolin-4-on-2-ylamino)-2,1,3-benzothiadiazoleDetails
Route of eliminationApproximately 95% of an administered dose is metabolized.
Half life2.5 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8592
Caco-2 permeable+0.5323
P-glycoprotein substrateSubstrate0.6545
P-glycoprotein inhibitor INon-inhibitor0.8365
P-glycoprotein inhibitor IINon-inhibitor0.7953
Renal organic cation transporterInhibitor0.6577
CYP450 2C9 substrateNon-substrate0.7953
CYP450 2D6 substrateNon-substrate0.8018
CYP450 3A4 substrateNon-substrate0.5795
CYP450 1A2 substrateNon-inhibitor0.5248
CYP450 2C9 inhibitorNon-inhibitor0.7117
CYP450 2D6 inhibitorNon-inhibitor0.7867
CYP450 2C19 inhibitorNon-inhibitor0.6353
CYP450 3A4 inhibitorNon-inhibitor0.781
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.6538
CarcinogenicityNon-carcinogens0.8915
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6573 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6935
hERG inhibition (predictor II)Non-inhibitor0.8907
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Acorda therapeutics inc
  • Actavis elizabeth llc
  • Actavis totowa llc
  • Alphapharm party ltd
  • Apotex inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Dr reddys laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Kit
Tabletoral4 mg
Tabletoral2 mg
Tabletoral4.576 mg/1
Capsuleoral2 mg/1
Capsuleoral4 mg/1
Capsuleoral6 mg/1
Capsule, gelatin coatedoral2 mg/1
Capsule, gelatin coatedoral4 mg/1
Capsule, gelatin coatedoral6 mg/1
Tabletoral2 mg/1
Tabletoral4 mg/1
Prices
Unit descriptionCostUnit
Zanaflex 6 mg capsule4.79USD capsule
Zanaflex 4 mg capsule3.2USD capsule
Zanaflex 2 mg capsule2.52USD capsule
Zanaflex 4 mg tablet2.29USD tablet
Tizanidine hcl 4 mg tablet1.49USD tablet
Zanaflex 2 mg tablet1.42USD tablet
Tizanidine hcl 2 mg tablet1.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6455557 No2001-11-282021-11-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.133 mg/mLALOGPS
logP1.6ALOGPS
logP2.02ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)7.49ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.2 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity64.77 m3·mol-1ChemAxon
Polarizability23.97 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udi-5490000000-5ee0610f321160b63c82View in MoNA
References
Synthesis Reference

Pavel Hradil, Lubomir Kvapil, Martin Grepl, Jan Novotny, “METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE.” U.S. Patent US20110263863, issued October 27, 2011.

US20110263863
General ReferencesNot Available
External Links
ATC CodesM03BX02
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelDownload (145 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tizanidine.
AbirateroneThe serum concentration of Tizanidine can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tizanidine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tizanidine.
AcetazolamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Tizanidine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tizanidine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tizanidine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tizanidine.
AliskirenThe risk or severity of adverse effects can be increased when Tizanidine is combined with Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tizanidine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tizanidine.
AlprenololTizanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Tizanidine.
AmineptineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Amineptine.
AmiodaroneTizanidine may increase the bradycardic activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tizanidine.
AmitriptylineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amitriptyline.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Tizanidine.
AmobarbitalAmobarbital may increase the hypotensive activities of Tizanidine.
AmobarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tizanidine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amyl Nitrite.
AnagrelideTizanidine may increase the QTc-prolonging activities of Anagrelide.
ApraclonidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Apraclonidine.
AripiprazoleAripiprazole may increase the hypotensive activities of Tizanidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with Aripiprazole.
ArotinololTizanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
Arsenic trioxideTizanidine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherTizanidine may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tizanidine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tizanidine.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Tizanidine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tizanidine.
AzelastineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tizanidine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Tizanidine is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Tizanidine can be increased when it is combined with Azithromycin.
AzithromycinTizanidine may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tizanidine.
BarbitalBarbital may increase the hypotensive activities of Tizanidine.
BarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Barbital.
BedaquilineTizanidine may increase the QTc-prolonging activities of Bedaquiline.
BefunololTizanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilTizanidine may increase the hypotensive activities of Benazepril.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tizanidine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Tizanidine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tizanidine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tizanidine.
BeractantTizanidine may increase the bradycardic activities of Beractant.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Tizanidine.
BevantololTizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Tizanidine.
BopindololTizanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibThe serum concentration of Tizanidine can be increased when it is combined with Bortezomib.
BretyliumBretylium may increase the bradycardic activities of Tizanidine.
BretyliumThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
BrimonidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tizanidine.
BrompheniramineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tizanidine.
BufuralolTizanidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BumetanideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tizanidine.
BupranololTizanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tizanidine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tizanidine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tizanidine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tizanidine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tizanidine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tizanidine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tizanidine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tizanidine.
CaffeineThe serum concentration of Tizanidine can be increased when it is combined with Caffeine.
CalfactantTizanidine may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Tizanidine is combined with Candesartan.
CandoxatrilTizanidine may increase the hypotensive activities of Candoxatril.
CaptoprilTizanidine may increase the hypotensive activities of Captopril.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tizanidine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tizanidine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tizanidine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tizanidine.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Tizanidine.
CarvedilolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Carvedilol.
CeliprololTizanidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.
CeritinibTizanidine may increase the bradycardic activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tizanidine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tizanidine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tizanidine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tizanidine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tizanidine.
ChloroquineTizanidine may increase the QTc-prolonging activities of Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorphenamine.
ChlorpromazineTizanidine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tizanidine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tizanidine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tizanidine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tizanidine.
CilazaprilTizanidine may increase the hypotensive activities of Cilazapril.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tizanidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tizanidine.
CiprofloxacinTizanidine may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideTizanidine may increase the QTc-prolonging activities of Cisapride.
CitalopramThe serum concentration of Tizanidine can be increased when it is combined with Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Tizanidine is combined with Citalopram.
ClarithromycinTizanidine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tizanidine.
ClevidipineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Tizanidine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tizanidine.
ClomipramineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clomipramine.
ClomipramineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tizanidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tizanidine.
ClotrimazoleThe serum concentration of Tizanidine can be increased when it is combined with Clotrimazole.
ClozapineTizanidine may increase the QTc-prolonging activities of Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tizanidine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tizanidine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tizanidine.
CrizotinibTizanidine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibCrizotinib may increase the bradycardic activities of Tizanidine.
CyclizineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclizine.
CyclobenzaprineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tizanidine.
Cyproterone acetateThe serum concentration of Tizanidine can be decreased when it is combined with Cyproterone acetate.
DantroleneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dantrolene.
DapagliflozinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tizanidine.
DapoxetineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapoxetine.
DeferasiroxThe serum concentration of Tizanidine can be increased when it is combined with Deferasirox.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Tizanidine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tizanidine.
DesipramineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Desloratadine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Tizanidine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tizanidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tizanidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tizanidine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tizanidine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tizanidine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tizanidine.
DiclofenamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Diclofenamide.
DifenoxinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Difenoxin.
DigoxinDigoxin may increase the bradycardic activities of Tizanidine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tizanidine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tizanidine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tizanidine.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Tizanidine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dimenhydrinate.
DinutuximabThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tizanidine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tizanidine.
DipyridamoleThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dipyridamole.
DisopyramideTizanidine may increase the QTc-prolonging activities of Disopyramide.
DofetilideTizanidine may increase the QTc-prolonging activities of Dofetilide.
DolasetronTizanidine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneTizanidine may increase the QTc-prolonging activities of Domperidone.
DonepezilTizanidine may increase the bradycardic activities of Donepezil.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tizanidine.
DosulepinThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Dosulepin.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Tizanidine.
DoxepinThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
DoxylamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tizanidine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
DronedaroneTizanidine may increase the bradycardic activities of Dronedarone.
DroperidolTizanidine may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Tizanidine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tizanidine.
DuloxetineTizanidine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineDuloxetine may decrease the antihypertensive activities of Tizanidine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tizanidine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tizanidine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tizanidine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tizanidine.
EliglustatTizanidine may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.
EnalaprilTizanidine may increase the hypotensive activities of Enalapril.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tizanidine.
EnalaprilatTizanidine may increase the hypotensive activities of Enalaprilat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tizanidine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tizanidine.
EplerenoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eplerenone.
EprosartanThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eprosartan.
ErythromycinTizanidine may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Tizanidine is combined with Escitalopram.
EsmirtazapineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Esmirtazapine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Tizanidine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tizanidine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tizanidine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.
EthanolTizanidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Tizanidine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tizanidine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tizanidine.
EthotoinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tizanidine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tizanidine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tizanidine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tizanidine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tizanidine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tizanidine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tizanidine.
EtoperidoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tizanidine.
EzogabineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felbamate.
FelodipineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tizanidine.
FenfluramineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tizanidine.
FexofenadineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fexofenadine.
FingolimodTizanidine may increase the bradycardic activities of Fingolimod.
FlecainideTizanidine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tizanidine.
FlunarizineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tizanidine.
FluoxetineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tizanidine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tizanidine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tizanidine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tizanidine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tizanidine.
FluvoxamineThe serum concentration of Tizanidine can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fluvoxamine.
FosinoprilTizanidine may increase the hypotensive activities of Fosinopril.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tizanidine.
FosphenytoinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tizanidine.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Tizanidine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tizanidine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tizanidine is combined with gabapentin enacarbil.
Gadobenic acidTizanidine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the bradycardic activities of Tizanidine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tizanidine.
GemifloxacinTizanidine may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tizanidine.
GoserelinTizanidine may increase the QTc-prolonging activities of Goserelin.
GranisetronTizanidine may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tizanidine.
HaloperidolTizanidine may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tizanidine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tizanidine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tizanidine.
HexobarbitalHexobarbital may increase the hypotensive activities of Tizanidine.
HexobarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hexobarbital.
HydralazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tizanidine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tizanidine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
HydroxyzineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydroxyzine.
IbutilideTizanidine may increase the QTc-prolonging activities of Ibutilide.
IloperidoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Iloperidone.
ImipramineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indapamide.
IndenololTizanidine may increase the atrioventricular blocking (AV block) activities of Indenolol.
IrbesartanThe risk or severity of adverse effects can be increased when Tizanidine is combined with Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tizanidine.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Tizanidine.
IvabradineTizanidine may increase the bradycardic activities of Ivabradine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tizanidine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tizanidine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tizanidine.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Tizanidine.
LacosamideTizanidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tizanidine.
LanreotideTizanidine may increase the bradycardic activities of Lanreotide.
LenvatinibTizanidine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideTizanidine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levetiracetam.
LevobunololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tizanidine.
LevocabastineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levocetirizine.
LevodopaTizanidine may increase the orthostatic hypotensive activities of Levodopa.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tizanidine.
LevofloxacinTizanidine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tizanidine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Tizanidine.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tizanidine.
LidocaineThe serum concentration of Tizanidine can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Lidocaine.
LisinoprilTizanidine may increase the hypotensive activities of Lisinopril.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tizanidine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Tizanidine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tizanidine.
LopinavirTizanidine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tizanidine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tizanidine.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tizanidine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tizanidine.
Lu AA21004The risk or severity of adverse effects can be increased when Tizanidine is combined with Lu AA21004.
LucinactantTizanidine may increase the bradycardic activities of Lucinactant.
LumefantrineTizanidine may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tizanidine is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tizanidine.
MeclizineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tizanidine.
MefloquineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tizanidine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tizanidine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tizanidine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tizanidine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tizanidine.
MethadoneTizanidine may increase the QTc-prolonging activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tizanidine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tizanidine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tizanidine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tizanidine.
MethazolamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tizanidine.
MethohexitalMethohexital may increase the hypotensive activities of Tizanidine.
MethohexitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tizanidine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tizanidine.
MethsuximideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Tizanidine.
MethyldopaThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Tizanidine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methylphenobarbital.
MetipranololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Tizanidine.
MetyrosineTizanidine may increase the sedative activities of Metyrosine.
MexiletineThe serum concentration of Tizanidine can be increased when it is combined with Mexiletine.
MianserinThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Tizanidine.
MilnacipranThe risk or severity of adverse effects can be increased when Tizanidine is combined with Milnacipran.
MilnacipranMilnacipran may decrease the antihypertensive activities of Tizanidine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Tizanidine.
MirtazapineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mirtazapine.
MoexiprilTizanidine may increase the hypotensive activities of Moexipril.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tizanidine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tizanidine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tizanidine.
MoxifloxacinTizanidine may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
NabiloneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nabilone.
NadololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tizanidine.
NebivololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nebivolol.
NesiritideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nesiritide.
NevirapineThe serum concentration of Tizanidine can be increased when it is combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Tizanidine.
NicorandilNicorandil may increase the hypotensive activities of Tizanidine.
NifedipineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nifedipine.
NilotinibTizanidine may increase the QTc-prolonging activities of Nilotinib.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Tizanidine.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Tizanidine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tizanidine.
NitroglycerinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nitroglycerin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Tizanidine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tizanidine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tizanidine.
NortriptylineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nortriptyline.
OctreotideOctreotide may increase the bradycardic activities of Tizanidine.
OfloxacinTizanidine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Olanzapine.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tizanidine.
OlopatadineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Olopatadine.
OmapatrilatTizanidine may increase the hypotensive activities of Omapatrilat.
OndansetronTizanidine may increase the QTc-prolonging activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tizanidine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tizanidine.
OrlistatThe serum concentration of Tizanidine can be decreased when it is combined with Orlistat.
OrphenadrineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tizanidine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tizanidine.
OsimertinibThe serum concentration of Tizanidine can be decreased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tizanidine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tizanidine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tizanidine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tizanidine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tizanidine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tizanidine.
PanobinostatTizanidine may increase the QTc-prolonging activities of Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Papaverine.
ParaldehydeTizanidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Tizanidine.
ParoxetineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Paroxetine.
PasireotideTizanidine may increase the bradycardic activities of Pasireotide.
PazopanibTizanidine may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.
PenbutololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Penbutolol.
PentamidineTizanidine may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Tizanidine.
PentobarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Tizanidine is combined with Perampanel.
PerflutrenTizanidine may increase the QTc-prolonging activities of Perflutren.
PerindoprilTizanidine may increase the hypotensive activities of Perindopril.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tizanidine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tizanidine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tizanidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tizanidine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Tizanidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tizanidine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tizanidine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tizanidine.
PindololThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tizanidine.
PipotiazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pomalidomide.
Poractant alfaTizanidine may increase the bradycardic activities of Poractant alfa.
PractololTizanidine may increase the atrioventricular blocking (AV block) activities of Practolol.
PramipexoleTizanidine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tizanidine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tizanidine.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Tizanidine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tizanidine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tizanidine.
PrimaquineTizanidine may increase the QTc-prolonging activities of Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Tizanidine.
PrimidoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Primidone.
ProcainamideTizanidine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tizanidine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.
PromazineTizanidine may increase the QTc-prolonging activities of Promazine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tizanidine.
PromethazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Promethazine.
PropafenoneTizanidine may increase the QTc-prolonging activities of Propafenone.
PropafenonePropafenone may increase the bradycardic activities of Tizanidine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tizanidine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tizanidine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tizanidine.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Tizanidine.
ProtriptylineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tizanidine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tizanidine.
QuetiapineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Quetiapine.
QuinaprilTizanidine may increase the hypotensive activities of Quinapril.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tizanidine.
QuinidineTizanidine may increase the QTc-prolonging activities of Quinidine.
QuinineTizanidine may increase the QTc-prolonging activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ramelteon.
RamiprilTizanidine may increase the hypotensive activities of Ramipril.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tizanidine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tizanidine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tizanidine.
RescinnamineTizanidine may increase the hypotensive activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tizanidine.
RifampicinThe metabolism of Tizanidine can be increased when combined with Rifampicin.
RiociguatThe risk or severity of adverse effects can be increased when Tizanidine is combined with Riociguat.
RisperidoneTizanidine may increase the hypotensive activities of Risperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tizanidine.
RivastigmineTizanidine may increase the bradycardic activities of Rivastigmine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tizanidine.
RopiniroleTizanidine may increase the sedative activities of Ropinirole.
RopiniroleThe serum concentration of Tizanidine can be increased when it is combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tizanidine.
RotigotineTizanidine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tizanidine.
RuxolitinibRuxolitinib may increase the bradycardic activities of Tizanidine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tizanidine.
SaquinavirTizanidine may increase the QTc-prolonging activities of Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Tizanidine.
SecobarbitalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tizanidine.
SertralineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tizanidine.
SimeprevirThe serum concentration of Tizanidine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Tizanidine.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Tizanidine.
SpiraprilTizanidine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Tizanidine.
StiripentolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Stiripentol.
SufentanilTizanidine may increase the bradycardic activities of Sufentanil.
SulfisoxazoleTizanidine may increase the QTc-prolonging activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tizanidine.
SuvorexantThe risk or severity of adverse effects can be increased when Tizanidine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tasimelteon.
TelavancinTizanidine may increase the QTc-prolonging activities of Telavancin.
TelithromycinTizanidine may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Tizanidine is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tizanidine.
TemocaprilTizanidine may increase the hypotensive activities of Temocapril.
TenofovirThe serum concentration of Tizanidine can be increased when it is combined with Tenofovir.
TerazosinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Terazosin.
TeriflunomideThe serum concentration of Tizanidine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tizanidine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tizanidine.
ThalidomideTizanidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tizanidine.
TheophyllineThe serum concentration of Tizanidine can be increased when it is combined with Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Tizanidine.
ThiamylalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Thiamylal.
ThiopentalThiopental may increase the hypotensive activities of Tizanidine.
ThiopentalThe risk or severity of adverse effects can be increased when Tizanidine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tizanidine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tizanidine.
TiagabineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tiagabine.
TianeptineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Tianeptine.
TiclopidineThe serum concentration of Tizanidine can be increased when it is combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tizanidine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Tizanidine.
TofacitinibTofacitinib may increase the bradycardic activities of Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tizanidine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tizanidine.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine.
ToremifeneTizanidine may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tizanidine.
TrandolaprilTizanidine may increase the hypotensive activities of Trandolapril.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tizanidine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tizanidine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tizanidine.
TrazodoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trazodone.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Tizanidine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tizanidine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tizanidine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tizanidine.
TrimipramineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tizanidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tizanidine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine.
VandetanibTizanidine may increase the QTc-prolonging activities of Vandetanib.
VemurafenibThe serum concentration of Tizanidine can be increased when it is combined with Vemurafenib.
VemurafenibTizanidine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Tizanidine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Tizanidine.
VigabatrinThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tizanidine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tizanidine.
ZiconotideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tizanidine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tizanidine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tizanidine.
ZonisamideThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tizanidine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tizanidine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tizanidine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702. [PubMed:8930173 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
agonist
General Function:
Phosphatidylinositol binding
Specific Function:
Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK...
Gene Name:
NISCH
Uniprot ID:
Q9Y2I1
Molecular Weight:
166627.105 Da
References
  1. Rolon PA: Myxoglobulosis of the appendix. Int Surg. 1977 Jun-Jul;62(6-7):355-6. [PubMed:893017 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Shellenberger MK, Groves L, Shah J, Novack GD: A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. Drug Metab Dispos. 1999 Feb;27(2):201-4. [PubMed:9929503 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23